Last updated on September 2016

Phase 1/2a Study of BAL101553 Administered as 48-hour Intravenous Infusions in Adult Patients With Advanced Solid Tumors


Brief description of study

Single-agent, open-label, multi-center sequential dose escalation and expansion study of BAL101553, administered as an intravenous (IV) infusion over 48 hours to adults with advanced or recurrent solid tumors.

Detailed Study Description

This is the first study of prolonged intravenous infusion of BAL101553. BAL101553 will be administered as an intravenous infusion over 48 hours, to adults with advanced or recurrent solid tumors who have failed standard therapy, or for whom no effective standard therapy is available. The primary goal of the study is to find the highest dose of BAL101553 that can safely be given to humans and to assess what side effects occur. The study will start by treating patients with a low dose. Once it has been shown that this low dose is well tolerated, new patients will be treated at higher dose levels ("dose escalation"). Once the highest, well tolerated dose is identified, 40 new patients will be treated at that dose (this part is called "dose expansion") to further assess the tolerability and potential anticancer activity of oral BAL101553. The study will also measure pharmacokinetics, pharmacodynamic effects and assess biomarkers.

Clinical Study Identifier: NCT02895360

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Cristina Sessa, Prof

Oncology Institute of Southern Switzerland; Ospedale Regionale San Giovanni Bellinzona e Valli
Bellinzona, Switzerland
  Connect »

Roger von Moos, PD

Cantonal Hospital of Grisons, Department of Oncology/ Haematology
Chur, Switzerland
  Connect »

Markus Joerger, MD PhD

Cantonal Hospital of St. Gallen, Dep. Medical Oncology & Hematology
St. Gallen, Switzerland
  Connect »